Stay updated with breaking news from Ventricular Dysfunction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global DESTINY-Lung04 phase 3 trial evaluating the efficacy and safety of ENHERTU (trastuzumab
DESTINY-Breast03 data presented at SABCS 2021 showed Daiichi Sankyo and AstraZeneca's ENHERTU demonstrated a similar benefit in patient subgroups, including those with stable brain metastases, compared
Additional analyses of DESTINY-Breast03 trial of ENHERTU and updated results from triple negative breast cancer cohort of TROPION-PanTumor01 trial of datopotamab deruxtecan to be highlighted Daiichi
Heart of a 41-year-old woman was transplanted to 31-year-old man, who was suffering from dilated cardiomyopathy with severe left ventricular dysfunction: Global Hospital of Mumbai said.
Daiichi Sankyo Company, Limited: ENHERTU Receives Prime Minister's Award from the Japan Techno-Economics Society Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that ENHERTU (trastuzumab deruxtecan), a HER2 directed antibody drug conjugate (ADC), received the Prime Minister's Award at the 9 th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). The Technology Management and Innovation Awards were established in 2012 with the objective of contributing to the development of the nation's economy, social changes, and the pr...